Akebia Therapeutics (AKBA) Q3 2023: $18M COGS Decline Extends Cash Runway Ahead of PDUFA Catalyst
Akebia enters a pivotal pre-launch phase with regulatory clarity and cost discipline supporting its transition. The company’s focus on operational efficiency and strategic cash management positions it to capitalize on a potential Vatadustat U.S. launch in 2024. Investors face a binary event with the March PDUFA date, while legacy Auryxia cash flows fund the runway and mitigate near-term risk.
Summary
- PDUFA Catalyst Looms: March 2024 FDA decision on Vatadustat will define Akebia’s next chapter.
- Cost Structure Reset: Deep COGS and R&D cuts extend operational runway and support launch readiness.
- Legacy Cash Flow Bridge: Auryxia revenues and delayed debt payments underpin liquidity into 2024.
Business Overview
Akebia Therapeutics develops and commercializes therapies for kidney disease, with a business model spanning proprietary drug development and commercial sales. Its lead commercial asset, Auryxia, an oral iron-based phosphate binder, treats chronic kidney disease (CKD) patients on dialysis. The near-term growth lever is Vatadustat, an oral HIF-PH inhibitor for anemia in CKD, currently pending FDA approval. The company generates revenue primarily from Auryxia sales, while future growth depends on successful U.S. commercialization of Vatadustat and international partnerships.
Performance Analysis
Akebia’s Q3 2023 results reflect a deliberate pivot toward cost containment and launch preparation. Total revenues reached $42 million, with Auryxia net product revenue at $40.1 million, down from the prior year due to volume and payer mix shifts, but partially offset by price increases. Management continues to expect full-year Auryxia revenue near $170 million, providing a stable cash bridge as the brand nears loss of exclusivity in 2025.
Cost discipline was the quarter’s defining feature: Cost of goods sold (COGS) fell sharply to $18 million, driven by lower inventory write-downs and reduced sales volume, while R&D and SG&A expenses dropped meaningfully as development and commercial spending wound down ahead of the Vatadustat launch. The net loss narrowed to $14.5 million, a substantial improvement from the prior year’s $54.1 million loss, reflecting both the operational reset and focus on cash preservation.
- COGS Compression: The $20.3 million YoY decrease in COGS reflects inventory and volume management, supporting cash flow.
- SG&A and R&D Rationalization: Headcount reductions and targeted cuts in marketing and clinical spend lower the cost base.
- Debt Service Extension: Favorable Pharmakon loan amendments delay principal payments, preserving liquidity for launch investment.
With $48.2 million in cash and equivalents and ongoing Auryxia cash generation, Akebia expects to fund operations well into the anticipated Vatadustat launch window.
Executive Commentary
"We completed a formal dispute process and engaged with the FDA during an end-of-dispute Type A meeting. We then resubmitted to our NDA for Vatadustat in September...we're now shifting our focus to the Vatadustat launch phase that we expect next year if Vatadustat's approved."
John Butler, Chief Executive Officer
"Our priority continues to be focused on strengthening our balance sheet as we enter a potential launch year...The favorable modification to payment terms enables us to strategically invest in the Vatadustat launch activities, while also continuing to maximize Auryxia revenue for the remainder of the year and into 2024."
Ellen Snow, Chief Financial Officer
Strategic Positioning
1. Regulatory Pathway and U.S. Launch Readiness
Vatadustat’s PDUFA date of March 27, 2024, is the central catalyst, with Akebia leveraging extensive post-marketing safety data and productive FDA engagement to strengthen its regulatory case. The team is preparing for a rapid launch, with commercial supply and sales infrastructure in place, and expects to invest incrementally relative to its current cost base.
2. Commercial Leverage and Market Access
Akebia’s commercial sales team is already embedded in the dialysis channel via Auryxia, creating significant overlap and cross-sell potential for Vatadustat. The CSL Vifor partnership provides access to up to 60% of U.S. dialysis centers, particularly those aligned with Fresenius, while Akebia retains full economics for DaVita and other uncovered providers.
3. Payer and Reimbursement Strategy
The U.S. dialysis reimbursement landscape is complex, with most CKD anemia drugs paid via a bundled Medicare payment. The transitional add-on payment adjustment (TDAPA) will reimburse Vatadustat at cost for two years post-approval, after which pricing must adapt to bundled economics. Akebia is lobbying for more innovation-friendly policies post-TDAPA but acknowledges likely price compression after the initial window.
4. International Expansion and Royalties
Vatadustat is now approved in 36 countries, including recent wins in Australia and Taiwan. The upcoming European launch by partner Medice in 2024 could drive milestone and royalty income, although the U.S. remains the dominant value driver.
5. Legacy Business Optimization
Auryxia continues to provide meaningful cash flow, with management exiting unfavorable payer contracts and targeting price increases to offset volume pressure. The brand’s maturity and impending loss of exclusivity in 2025 are acknowledged, but Akebia expects stable volumes and incremental revenue growth in the near term.
Key Considerations
Akebia’s Q3 marks a clear transition from regulatory uncertainty to operational execution, with the balance sheet and infrastructure aligned for a pivotal 2024. The company’s ability to bridge to the Vatadustat launch without dilutive financing is a key differentiator among small-cap biotech peers.
Key Considerations:
- Binary Regulatory Event: The Vatadustat PDUFA decision is a make-or-break moment for valuation and future growth.
- Commercial Execution Risk: Success hinges on rapid uptake and market access in a concentrated, protocol-driven dialysis market.
- Reimbursement Uncertainty: Post-TDAPA pricing and Medicare Advantage coverage remain unresolved, impacting long-term profitability.
- Cash Runway Management: Delayed debt payments and disciplined OpEx are essential to avoid near-term capital raises.
Risks
Akebia faces substantial regulatory and commercial risk, with the upcoming FDA decision on Vatadustat the single largest variable. Failure to secure approval or a highly restrictive label would materially impair growth prospects. The evolving Medicare reimbursement landscape, especially post-TDAPA, introduces further uncertainty around sustainable pricing and access. Competition from established ESAs and other HIF-PH inhibitors, as well as Auryxia’s loss of exclusivity in 2025, could compress cash flows and strategic flexibility.
Forward Outlook
For Q4 2023, Akebia guided to:
- Full-year Auryxia net product revenue around $170 million
- Stable volume with incremental pricing upside as unfavorable payer contracts are exited
For full-year 2024, management expects:
- Vatadustat launch readiness pending FDA approval in March 2024
- Operational runway funded through Auryxia cash flow and delayed debt payments
Management highlighted several factors that will drive results:
- Regulatory progress and FDA engagement on Vatadustat
- Commercial leverage from existing dialysis relationships and CSL Vifor partnership
Takeaways
Akebia’s investment case is binary and time-sensitive, with near-term value tied to regulatory approval and commercial execution of Vatadustat. Cost discipline and balance sheet moves provide a bridge, but long-term success requires rapid market penetration and favorable reimbursement outcomes.
- Regulatory Binary: The March 2024 PDUFA date is the critical inflection point for Akebia’s trajectory, with operational and financial levers aligned for launch if approved.
- Commercial Leverage: Existing sales infrastructure and partnerships position Akebia to capture share quickly, but execution risk remains high given payer and protocol complexity.
- Future Watchpoint: Investors should monitor label negotiations, TDAPA reimbursement policy, and early launch traction for evidence of durable franchise value.
Conclusion
Akebia’s Q3 2023 results underscore disciplined execution ahead of a defining regulatory event. The company’s ability to control costs, extend its cash runway, and prepare for a major launch sets up a high-stakes 2024. The coming quarters will be shaped by the FDA’s decision and Akebia’s agility in navigating the U.S. dialysis market.
Industry Read-Through
Akebia’s experience highlights the challenges and opportunities for small biotechs navigating late-stage regulatory and commercial hurdles. The TDAPA reimbursement window and bundled payment complexities are industry-wide issues for novel therapies targeting Medicare-heavy populations. Competitors in the renal anemia and broader nephrology space should note the importance of payer strategy, cross-sell infrastructure, and capital discipline. The evolving Medicare Advantage penetration and policy shifts will shape market access for all CKD-focused assets, while the emphasis on operational runway management is instructive for peers facing similar launch timelines and binary catalysts.